aortic valve replacement for stenosis
Protocol: SITE00000058
Full Title
Medtronic Optimize PRO TAVR Post Market Study
Description
This study enrolls adults who are scheduled to have an aortic valve replacement for disease the aortic valve called aortic stenosis. The Evolut PRO and Evolut PRO+ systems are FDA approved for treating aortic stenosis, so in this study we just want to collect data. The purpose of this study is to learn more about how well this device works.

Your participation in the study will last about 1 year. You will have study visits in person and by phone during that time. Please contact our study team to learn more about what this study involves. Study takes place at Gates Vascular Institute.

Technical Description

The purpose of this study is to collect clinical evidence on valve
performance and procedural outcomes associated with an ???optimized??? TAVR care pathway and using the EvolutTM PRO and EvolutTM PRO+ devices
Compensation: No
Eligibility
-Adults ages 18+.
-Have symptoms from aortic valve stenosis.
-Will be having aortic valve replacement.
Age Group: Adults
Principal Investigator: VIJAY IYER
ClinicalTrials.gov: Open Study
Contact(s)
ROBIN STEIN
rmstein3@buffalo.edu
+1 716-888-4859
Want to Learn More?
Enrollment Update

Due to COVID-19, new enrollment in research studies will be greatly limited. If you are interested in a study, there may be a longer waiting period to receive a response to your inquiry. View the guidance for research participants for additional information.

Let us know how the study team can reach you. If you do not hear back within 2 business days, reach out to the study team directly at the contact information above or email ctsiresearch@buffalo.edu and someone will assist you.